Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Autoimmune Disorders

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 93 articles:
HTML format



Single Articles


    March 2024
  1. MARGONI M, Pagani E, Meani A, Preziosa P, et al
    Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric Multiple Sclerosis.
    Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911.
    PubMed     Abstract available


    February 2024
  2. FADDA G, Yea C, O'Mahony J, Waters P, et al
    Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
    Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890.
    PubMed     Abstract available


  3. SHU Y, Huang R, Li Q, Lu Y, et al
    Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Is Associated with HLA-A*3303 and HLA-DPB1*0501.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26899.
    PubMed     Abstract available


  4. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    PubMed     Abstract available


    December 2023
  5. NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al
    High levels of perivascular inflammation and active demyelinating lesions at time of death associated with rapidly progressive multiple sclerosis disease course: a retrospective post-mortem cohort study.
    Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870.
    PubMed     Abstract available


  6. MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al
    Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
    Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840.
    PubMed     Abstract available


  7. KIM S, Eun MY, Lee JJ, Seok HY, et al
    Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859.
    PubMed    


  8. VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A
    Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions".
    Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856.
    PubMed    


  9. KNOWLES S, Middleton R, Cooze B, Farkas I, et al
    Comparing the pathology, clinical and demographic characteristics of younger and older-onset multiple sclerosis.
    Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843.
    PubMed     Abstract available


    November 2023
  10. KREFT KL, Uzochukwu E, Loveless S, Willis M, et al
    Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort.
    Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831.
    PubMed     Abstract available


    October 2023
  11. MAJED M, Valencia Sanchez C, Bennett JL, Fryer J, et al
    Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.
    Ann Neurol. 2023;94:727-735.
    PubMed     Abstract available


    September 2023
  12. GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al
    A genetic risk variant for multiple sclerosis severity is associated with brain atrophy.
    Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807.
    PubMed     Abstract available


  13. VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al
    MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis.
    Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793.
    PubMed     Abstract available


    August 2023
  14. ADINGUPU DD, Evans T, Soroush A, Hansen A, et al
    Temporal pattern of cortical hypoxia in Multiple Sclerosis and its significance on neuropsychological and clinical measures of disability.
    Ann Neurol. 2023 Aug 22. doi: 10.1002/ana.26769.
    PubMed     Abstract available


    July 2023
  15. SORMANI MP, Schiavetti I, Ponzano M, Colato E, et al
    Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Cognition in Multiple Sclerosis.
    Ann Neurol. 2023 Jul 26. doi: 10.1002/ana.26751.
    PubMed     Abstract available


  16. XIE Y, Chen B, Wang Q, Chen X, et al
    Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model.
    Ann Neurol. 2023;94:163-181.
    PubMed     Abstract available


    June 2023
  17. YANG B, Brown A, McKeon A, Ahlskog JE, et al
    Tenascin-R autoimmunity: isolated tremor reversed with immunotherapy.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26730.
    PubMed     Abstract available


  18. CLARK KA, Manning AR, Chen L, Liu F, et al
    Early MRI features of new paramagnetic rim lesions in Multiple Sclerosis.
    Ann Neurol. 2023 Jun 21. doi: 10.1002/ana.26727.
    PubMed     Abstract available


  19. PITTOCK SJ, Barnett M, Bennett JL, Berthele A, et al
    Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Ann Neurol. 2023;93:1053-1068.
    PubMed     Abstract available


  20. YIN HX, Wang YJ, Liu MG, Zhang DD, et al
    Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants.
    Ann Neurol. 2023;93:1069-1081.
    PubMed     Abstract available


    May 2023
  21. HOLM HANSEN R, von Essen MR, Mahler MR, Cobanovic S, et al
    Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis.
    Ann Neurol. 2023 May 16. doi: 10.1002/ana.26684.
    PubMed     Abstract available


  22. PATRICK MT, Nair RP, He K, Stuart PE, et al
    Shared Genetic Risk Factors for Multiple Sclerosis/Psoriasis Suggest Involvement of Interleukin-17 and Janus Kinase-Signal Transducers and Activators of Transcription Signaling.
    Ann Neurol. 2023 May 1. doi: 10.1002/ana.26672.
    PubMed     Abstract available


    April 2023
  23. HAMZAOUI M, Garcia J, Boffa G, Lazzarotto A, et al
    Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression.
    Ann Neurol. 2023 Apr 11. doi: 10.1002/ana.26657.
    PubMed     Abstract available


    March 2023
  24. BAKIRTZIS C, Langdon DW, Grigoriadis N
    Time to rebaseline cognitive performance in people with multiple sclerosis?
    Ann Neurol. 2023 Mar 8. doi: 10.1002/ana.26628.
    PubMed    


  25. GALARDI MM, Sowa GM, Crockett CD, Rudock R, et al
    Pathogen and Antibody Identification in Children with Encephalitis in Myanmar.
    Ann Neurol. 2023;93:615-628.
    PubMed     Abstract available


    February 2023
  26. KALLURI HV, Rosebraugh MR, Misko TP, Ziemann A, et al
    Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants.
    Ann Neurol. 2023;93:285-296.
    PubMed     Abstract available


    January 2023
  27. SALVARANI C, Paludo J, Hunder GG, Ansell SM, et al
    Exploring Gene Expression Profiles in Primary Central Nervous System Vasculitis.
    Ann Neurol. 2023;93:120-130.
    PubMed     Abstract available


  28. STREDNY CM, Blessing MM, Yi V, Ryan ME, et al
    Mimics of Pediatric Small Vessel Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2023;93:109-119.
    PubMed     Abstract available


    December 2022
  29. PAYET CA, You A, Fayet OM, Hemery E, et al
    Central role of macrophages and nucleic acid release in Myasthenia Gravis thymus.
    Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26590.
    PubMed     Abstract available


  30. VAN DEN BOSCH AMR, Hummert S, Steyer A, Ruhwedel T, et al
    Ultrastructural Axon-Myelin Unit Alterations in Multiple Sclerosis Correlate with Inflammation.
    Ann Neurol. 2022 Dec 24. doi: 10.1002/ana.26585.
    PubMed     Abstract available


  31. ZHANG Y, Zhou Q, Peng L, Chen S, et al
    Increased cerebellum (18) F-DPA-714 uptake in anti-Gluk2-autoimmune encephalitis.
    Ann Neurol. 2022 Dec 8. doi: 10.1002/ana.26563.
    PubMed    


  32. NGUYEN S, Bastien E, Chretien B, Sassier M, et al
    Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
    Ann Neurol. 2022;92:1080-1089.
    PubMed     Abstract available


    November 2022
  33. OKUDA DT, Kantarci O, Lebrun-Frenay C, Sormani MP, et al
    Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome.
    Ann Neurol. 2022 Nov 18. doi: 10.1002/ana.26555.
    PubMed     Abstract available


  34. GARCIA-MONTOJO M, Simula ER, Fathi S, McMahan C, et al
    Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.
    Ann Neurol. 2022;92:782-792.
    PubMed     Abstract available


    October 2022
  35. VAN KEMPEN ZLE, Hogenboom L, Toorop AA, Steenhuis M, et al
    Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis.
    Ann Neurol. 2022 Oct 17. doi: 10.1002/ana.26534.
    PubMed     Abstract available


  36. MURPHY OC, Sotirchos ES, Kalaitzidis G, Vasileiou E, et al
    Trans-synaptic degeneration following acute optic neuritis in multiple sclerosis.
    Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26529.
    PubMed     Abstract available


    September 2022
  37. KELLER CW, Chuquisana O, Derdelinckx J, Gross CC, et al
    Impaired B cell Expression of the Inhibitory Fcgamma Receptor IIB in Myasthenia Gravis.
    Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26507.
    PubMed     Abstract available


  38. GAUDIOSO CM, Mar S, Casper TC, Codden R, et al
    MOG and AQP4 antibodies among children with multiple sclerosis and controls.
    Ann Neurol. 2022 Sep 11. doi: 10.1002/ana.26502.
    PubMed     Abstract available


    August 2022
  39. LINDGREN U, Pullerits R, Lindberg C, Oldfors A, et al
    Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis.
    Ann Neurol. 2022;92:201-212.
    PubMed     Abstract available


    June 2022
  40. MAGLIOZZI R, Fadda G, Brown RA, Bar-Or A, et al
    "Ependymal-in" gradient of thalamic damage in progressive multiple sclerosis.
    Ann Neurol. 2022 Jun 24. doi: 10.1002/ana.26448.
    PubMed     Abstract available


  41. RAHMANZADEH R, Galbusera R, Lu PJ, Bahn E, et al
    A new advanced MRI biomarker for remyelinated lesions in Multiple Sclerosis.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26441.
    PubMed     Abstract available


  42. KOIZUMI N, Takasugi J, Ohara N, Kawamoto M, et al
    FDG-PET/CT of Giant Cell Arteritis With Normal Inflammatory Markers.
    Ann Neurol. 2022 Jun 6. doi: 10.1002/ana.26428.
    PubMed    


  43. OECHTERING J, Lincke T, Schaedelin S, Decard BF, et al
    Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
    Ann Neurol. 2022;91:814-820.
    PubMed     Abstract available


    May 2022
  44. CACCIAGUERRA L, Carotenuto A, Pagani E, Mistri D, et al
    MRI EVALUATION OF PERIVASCULAR SPACE ABNORMALITIES IN NEUROMYELITIS OPTICA.
    Ann Neurol. 2022 May 20. doi: 10.1002/ana.26419.
    PubMed     Abstract available


  45. ZEYDAN B, Rocca MA, Kantarci OH, Filippi M, et al
    Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS.
    Ann Neurol. 2022;91:734-735.
    PubMed    


  46. GHIROTTO B, Oliveira DF, Cipelli M, Basso PJ, et al
    MS-Driven Metabolic Alterations Are Recapitulated in iPSC-Derived Astrocytes.
    Ann Neurol. 2022;91:652-669.
    PubMed     Abstract available


  47. DIEBOLD M, Galli E, Kopf A, Sanderson N, et al
    Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Ann Neurol. 2022;91:676-681.
    PubMed     Abstract available


    April 2022
  48. MANDEL-BREHM C, Benson LA, Tran B, Kung AF, et al
    ZSCAN1 autoantibodies are associated with pediatric paraneoplastic ROHHAD.
    Ann Neurol. 2022 Apr 25. doi: 10.1002/ana.26380.
    PubMed     Abstract available


  49. BOSE G, Healy BC, Lokhande HA, Sotiropoulos MG, et al
    Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26370.
    PubMed     Abstract available


  50. IWAMOTO S, Itokazu T, Sasaki A, Kataoka H, et al
    RGMa Signal in Macrophages Induces Neutrophil-Related Astrocytopathy in NMO.
    Ann Neurol. 2022;91:532-547.
    PubMed     Abstract available


  51. DOETS AY, Walgaard C, Lingsma HF, Islam B, et al
    International Validation of the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score.
    Ann Neurol. 2022;91:521-531.
    PubMed     Abstract available


    March 2022
  52. KISTER I, Patskovsky Y, Curtin R, Pei J, et al
    Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study.
    Ann Neurol. 2022 Mar 15. doi: 10.1002/ana.26346.
    PubMed     Abstract available


  53. LANGER-GOULD A, Cheng SC, Li BH, Smith JB, et al
    Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26352.
    PubMed     Abstract available


  54. BRILL L, Raposo C, Rechtman A, Zveik O, et al
    SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab.
    Ann Neurol. 2022 Mar 4. doi: 10.1002/ana.26343.
    PubMed     Abstract available


  55. KORNEK B, Leutmezer F, Rommer PS, Koblischke M, et al
    B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.
    Ann Neurol. 2022;91:342-352.
    PubMed     Abstract available


    February 2022
  56. DE MEO E, Filippi M, Trojano M, Comi G, et al
    Comparing natural history of early and late onset pediatric multiple sclerosis.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26322.
    PubMed     Abstract available


  57. ZEKERIDOU A, Yang B, Lennon VA, Guo Y, et al
    Anti-Neuronal Nuclear Antibody 3 Autoimmunity targets Dachshund homolog 1.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26320.
    PubMed     Abstract available


  58. MCCOMBE JA, Flanagan EP, Chen JJ, Zekeridou A, et al
    Investigating the Immunopathogenic Mechanisms Underlying MOGAD.
    Ann Neurol. 2022;91:299-300.
    PubMed    


    January 2022
  59. MCKAY KA, Bedri SK, Manouchehrinia A, Stawiarz L, et al
    Reduction in cognitive processing speed surrounding multiple sclerosis relapse.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301.
    PubMed     Abstract available


    December 2021
  60. FLEISCHER V, Ciolac D, Gonzalez-Escamilla G, Grothe M, et al
    Subcortical volumes as early predictors of fatigue in multiple sclerosis.
    Ann Neurol. 2021 Dec 30. doi: 10.1002/ana.26290.
    PubMed     Abstract available


  61. BISCHOF A, Papinutto N, Keshavan A, Rajesh A, et al
    Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis.
    Ann Neurol. 2021 Dec 8. doi: 10.1002/ana.26281.
    PubMed     Abstract available


  62. HEINE J, Kopp UA, Klag J, Ploner CJ, et al
    Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.
    Ann Neurol. 2021;90:949-961.
    PubMed     Abstract available


  63. SANTYR B, Pejhan S, Zhang Q, Budhram A, et al
    Unilateral Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2021;90:999-1000.
    PubMed    


    November 2021
  64. ZRZAVY T, Endmayr V, Bauer J, Macher S, et al
    Neuropathological Variability within a Spectrum of NMDAR-Encephalitis.
    Ann Neurol. 2021;90:725-737.
    PubMed     Abstract available


  65. QUENDT C, Ochs J, Hausser-Kinzel S, Hausler D, et al
    Proinflammatory CD20(+) T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.
    Ann Neurol. 2021;90:834-839.
    PubMed     Abstract available


    October 2021
  66. MARAMATTOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Reply to 'Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis by Dr Pegat et al.
    Ann Neurol. 2021 Oct 27. doi: 10.1002/ana.26257.
    PubMed    


  67. PEGAT A, Vogrig A, Khouri C, Masmoudi K, et al
    Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis.
    Ann Neurol. 2021 Oct 26. doi: 10.1002/ana.26258.
    PubMed    


  68. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    PubMed     Abstract available


    September 2021
  69. KOCH MW, Kaur S, Sage K, Kim J, et al
    Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26239.
    PubMed     Abstract available


  70. OSOWICKI J, Morgan H, Harris A, Crawford NW, et al
    Guillain-Barre Syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines.
    Ann Neurol. 2021 Sep 15. doi: 10.1002/ana.26218.
    PubMed    


  71. ZUHORN F, Graf T, Klingebiel R, Schabitz WR, et al
    Postvaccinal Encephalitis after ChAdOx1 nCov-19.
    Ann Neurol. 2021;90:506-511.
    PubMed     Abstract available


    August 2021
  72. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    PubMed     Abstract available


  73. PAN S, Chan JR
    Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
    PubMed     Abstract available


  74. KOLB H, Absinta M, Beck ES, Ha SK, et al
    7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
    PubMed     Abstract available


  75. TEWKESBURY G, Song JW, Perrone CM
    Magnetic Resonance Imaging of Autoimmune GFAP Astrocytopathy.
    Ann Neurol. 2021 Aug 13. doi: 10.1002/ana.26195.
    PubMed    


    July 2021
  76. HANDUNNETTHI L, Knezevic B, Kasela S, Burnham KL, et al
    Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26169.
    PubMed     Abstract available


  77. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
    MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
    PubMed     Abstract available


  78. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    PubMed     Abstract available


  79. HAUSER SL
    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
    PubMed    


    June 2021
  80. ALLEN CM, Ramsamy S, Tarr AW, Tighe PJ, et al
    Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26144.
    PubMed     Abstract available


  81. MARAMMATOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26143.
    PubMed     Abstract available


  82. HARTUNG HP
    Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making.
    Ann Neurol. 2021;89:1084-1087.
    PubMed    


  83. WINGERCHUK DM, Fujihara K, Palace J, Berthele A, et al
    Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
    Ann Neurol. 2021;89:1088-1098.
    PubMed     Abstract available


    May 2021
  84. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
    Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
    Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
    PubMed     Abstract available


  85. BEUKER C, Wankner MC, Thomas C, Strecker JK, et al
    Characterization of extracranial giant cell arteritis with intracranial involvement and its rapidly progressive subtype.
    Ann Neurol. 2021 May 16. doi: 10.1002/ana.26101.
    PubMed    


  86. LANDA J, Guasp M, Miguez-Cabello F, Guimaraes J, et al
    Encephalitis with autoantibodies against the glutamate kainate receptors GluK2.
    Ann Neurol. 2021 May 5. doi: 10.1002/ana.26098.
    PubMed     Abstract available


  87. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    PubMed     Abstract available


    April 2021
  88. IZUKA S, Kobayashi T, Takahashi Y
    Tongue tremor in systemic lupus erythematosus.
    Ann Neurol. 2021 Apr 21. doi: 10.1002/ana.26088.
    PubMed    


  89. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    PubMed     Abstract available


  90. PETZOLD A
    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    PubMed    


  91. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    PubMed    


  92. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed     Abstract available


    January 2021
  93. DE BRUIJN MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, et al
    The Antibodies Contributing to focal Epilepsy Signs and symptoms (ACES) score.
    Ann Neurol. 2021 Jan 11. doi: 10.1002/ana.26013.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.